Vedanta Biosciences: GrowthDevelops microbiome-based oral therapies for prevention of recurrent C. difficile infectionOct 4, 2026RoundOSVedanta BiosciencesCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesEnterprise softwareGrowthNorth America